Development
Bristol-Myers Squibb Company
BMY
$48.44
$0.631.32%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -8.61% | -6.99% | -8.36% | 11.87% | 25.90% |
| Total Depreciation and Amortization | -1.22% | 0.00% | 0.20% | -0.08% | -7.55% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,070.37% | 108.64% | -147.88% | 46.46% | 3.42% |
| Change in Net Operating Assets | 193.81% | 117.12% | -25.00% | -196.94% | -379.27% |
| Cash from Operations | -10.50% | 151.78% | -36.46% | -10.16% | -10.33% |
| Capital Expenditure | 3.51% | -32.05% | 6.83% | 19.65% | -40.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -78.22% | -77.17% | -135.90% | 32.76% | 96.44% |
| Divestitures | -2.43% | 27.32% | -14.54% | -68.07% | 221.72% |
| Other Investing Activities | -6,245.45% | 113.75% | 1.23% | -108.40% | -20.07% |
| Cash from Investing | -228.29% | -24.62% | -56.67% | -117.31% | 158.29% |
| Total Debt Issued | 42,320.00% | -108.70% | -10.16% | -5.88% | 288.89% |
| Total Debt Repaid | -- | 100.00% | 85.43% | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -341.99% | -262.00% | 89.65% | -312.99% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 2.60% | 0.50% | -0.08% | -4.45% | 0.78% |
| Other Financing Activities | -39.02% | -22.64% | 157.61% | -151.40% | 237.74% |
| Cash from Financing | 118.74% | -137.46% | 28.75% | 6.04% | 28.55% |
| Foreign Exchange rate Adjustments | 305.26% | -375.00% | -161.54% | -86.32% | 243.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 561.03% | -37.56% | -124.91% | -120.25% | 145.55% |